Nearly 89 percent of healthcare organizations experienced data breaches according to a study conducted by Ponemon Institute in 2016. This risk has only grown since then
September Newsletter
What to expect from Golden Helix in 2020!

What to expect from Golden Helix in 2020!
By Andreas Scherer, PhD
President & CEO

Happy New Year! Certainly, I hope you had a relaxing time over the holidays with family and friends as well as a great start into the new year. 2019 was a real landmark year for Golden Helix. Please let me mention a few highlights: We launched VSClinical AMP in June 2019: This product is supporting the clinical variant interpretation based on ACMG & AMP guidelines. The product was an instant success...

Read More

New eBook Release: Cyber Security Strategies for NGS Testing Labs

New eBook Release: Cyber Security Strategies for NGS Testing Labs
By Andreas Scherer, PhD
President & CEO

I am delighted to be starting the year with releasing a new eBook, “Cyber Security Strategies for NGS Testing Labs”. The field of Precision Medicine is at the forefront of changing the face of healthcare. It changes how we diagnose patients and provides new treatment options that did not exist just a few years ago. It is data-driven by nature. As a result, this field is exposed to new challenges when it comes to ensuring data privacy and protection....

Read More

Introducing Drugs & Trials for Cancer Diagnostics

Introducing Drugs & Trials for Cancer Diagnostics
By Nathan Fortier, PhD
Director of Research

When interpreting a variant using the AMP/ASCO guidelines for somatic variant interpretation, clinicians must determine whether the variant can be considered a biomarker that affects clinical care by predicting sensitivity, resistance, or toxicity to a specific therapy. Such a determination requires the investigation of multiple evidence sources, including clinical trials, FDA approved therapies and peer-reviewed studies. Unfortunately, strong evidence linking specific genetic biomarkers to FDA-approved therapies only exists for a small number of cancers...

Read More

Customizing Your VSClinical Workflow

Customizing Your VSClinical Workflow
By Gabe Rudy
VP of Product & Engineering

Clinical labs offer a unique and sophisticated product that is performed repeatedly with high standards of quality. VarSeq was developed to provide labs with the customization required for clinical genetic tests in a repeatable workflow. On top of this, VSClinical offers additional parameters and choices that can be made when designing the test workflow. In this blog series, we will deep-dive into these options and considerations at play when configuring your NGS testing process with VSClinical...

Read More

CEO Corner
New eBook: Clinical Variant Analysis for Cancer

Nearly 89 percent of healthcare organizations experienced data breaches according to a study conducted by Ponemon Institute in 2016 (Source). This risk has only grown since then making the use of advanced, secure technologies involving genomic data necessary to ward off such attacks in the future. Golden Helix is proud to offer our clients a secure analytics pipeline so this concern can be eliminated completely. Earlier this month, I released an eBook on this subject covering the potential risks our industry faces and Golden Helix’s comprehensive solution. If you have not received your complimentary copy, you can request one on our site here. Fittingly, our VP of Product & Engineering, Gabe Rudy, also elaborated on this topic in a recent webcast. We are highly focused on protecting our clients – if this is a topic of interest to you and would like to talk to us directly, please reach out here and we will be in touch.

Upcoming Webcast

Introducing Drugs & Trials for Cancer Diagnostics
February 12, 2020 | 12:00 PM Eastern

When interpreting a variant using the AMP/ASCO guidelines for somatic variant interpretation, clinicians must determine whether the variant can be considered a biomarker that affects clinical care by predicting sensitivity, resistance, or toxicity to a specific therapy. Such a determination requires the investigation of multiple evidence sources, including clinical trials, FDA approved therapies and peer-reviewed studies. 

Register
Customer Success

Congratulations to all of our customers who have published this month! To highlight just a few:

"BDNF Val66Met Positive Players Demonstrate Diffusion Tensor Imaging Consistent with Impaired Myelination Associated With High Levels of Soccer Heading: Indication of a Potential Gene-Environment Interaction Mechanism" - Yun Freudenberg-Hua & Colleagues, Feinstein Institute for Medical Research / Published in Frontiers in Neurology 

"Genetic Variants in Toll-Like Receptor 4 are Associated with Lack of Steroid-Responsiveness in Pediatric ITP Patients" Jonathan Flanagan & Colleagues, Baylor College of Medicine / Published in the American Journal of Hematology

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.